Compound 7ai in treating ewing sarcoma by inhibiting otud7a
AssigneesThe University of North Carolina at Chapel Hill, Atomwise Inc.
InventorsPengda Liu, Siyuan Su, Ian Jonathan Davis, Christian Laggner
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions for targeting 0TUD7A, the compositions having a component sufficient to block and/or reduce OTUD7A-mediated deubiquitination of EWS-FLI1 in a cell. The component can be 7Ai and variants thereof. The compositions can be used to treat Ewing sarcoma (EWS). Methods of using the disclosed compositions are also disclosed, including methods of treating EWS in a subject.t
Claims23
A composition for targeting OTUD7A, the composition comprising a component sufficient to block and/or reduce OTUD7A-mediated deubiquitination of EWS-FLI1 in a cell, wherein the component comprises 7Ai and variants thereof.
4-6. (canceled)
(canceled)
An OTUD7A catalytic inhibitor, the catalytic inhibitor comprising a 7Ai compound or variant thereof.
A method of treating Ewing sarcoma and related conditions, the method comprising administering to a subject having Ewing sarcoma or suspected of suffering from Ewing sarcoma a composition comprising a component targeting a fusion oncoprotein, wherein the fusion oncoprotein comprises EWS-FLIT, wherein the component comprises 7Ai or variant thereof.
25-32. (canceled)
Dependencies are inferred from the claim text.